A prominent Emory University psychiatrist received at least $2.8 million in consulting fees from companies whose drugs he was evaluating and failed to report a third of it, congressional investigators studying medical conflicts of interest announced. The allegations against Charles B. Nemeroff, MD, Phd, are the latest in a series of such charges. They are also likely to alter the cozy relationships between prominent academics and the drug industry.